Business Wire India

DUBLIN a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced its financial guidance for the year ended December 31, 2017. For the full year 2017 revenue will be in the range of USD 1,700 - USD 1,750 million, representing growth of 2 - 5% and earnings per share will be in the range of USD 5.00 - USD 5.20, representing growth of 6 - 11%.

Takeda Pharmaceutical Company Limited announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Sarissa Capital, the holder of 6.6% of ARIAD’s common shares, as well as each of the members of ARIAD’s Board of Directors have agreed to tender their shares to Takeda pursuant to the offer

The Federation of Indian Chambers of Commerce and Industry (FICCI) - an apex business organization - announced the launch of Self-regulation Code of Conduct  for the E-pharmacy sector in the presence of Government dignitaries and the concerned stakeholders.

Major contributories to company’s spectacular performance in Q2 include its top selling bulk drugs Montelukast (an anti-asthmatic), Atorvastatin (statin) and Rosuvastatin (another statin drug), which registered a jump of 46 per cent, 33 per cent and 203 per cent respectively in their sales revenues. This apart, consumer health products promoted under Dr. Morepen umbrella brand i.e. Home Diagnostics, OTC (Over the Counter) products and Formulations also recorded excellent sales nos. for the quarter under consideration.

How often have you said this or heard people saying it? We forget many things in our daily lives, but there is a difference when we forget to take our prescribed medicines. If you missed yesterday’s medicines, you can’t take them today – the damage has already happened in your body. According to the World Health Organization, “Approximately 50% of patients do not take their medications as prescribed.” This can lead to significant increase in hospitalization, treatment failure and even death. As per studies 2.5 times increased risk of hospitalization for patients with diabetes.

Teva Pharmaceutical Industries Ltd. announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc

Jubilant Pharma Ltd, announced that the U.S. Food and Drug Administration has approved RUBY-FILL®, an innovative technology for Positron Emission Tomography (PET) myocardial perfusion imaging (MPI). Comprised of a Rubidium-82 (Rb-82) Generator and precedent setting Elution System, RUBY-FILL® is used to produce a personalized patient dose of Rubidium Rb 82 chloride used to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease (CAD) which is an important component of diagnosing CAD.

MSD, Verastem, Inc. and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non small cell lung and pancreatic cancers. The trial will run through the ECMC network at centres in Edinburgh-Dundee, Southampton, Glasgow, Leicester and Belfast.

[adsense:336x280:8701650588]

Nanobiomed Inc®., a nanomedicine and biotechnology company announced its leading-edge development of a new molecule for use in tissue and cancer diagnostics.